Full-Time

Senior GPS Systems Manager

Posted on 5/9/2026

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

Compensation Overview

$153k - $208.5k/yr

Silver Spring, MD, USA

Remote

Remote work within the United States is allowed; on-site presence in Silver Spring, MD is the designated work location.

Category
IT & Security (1)
Required Skills
C/C++
Oracle
Requirements
  • A Bachelor's degree or foreign equivalent in Computer Science, Computer Engineering or Software Engineering, and 9 years of experience in the position or in a related computer systems analyst, computer programmer or software engineer position.
  • Alternatively, a Master's Degree or foreign equivalent in Computer Science, Computer Engineering or Software Engineering, and 7 years of experience in the position or in a related computer systems analyst, computer programmer or software engineer position.
  • Must have 7 years of experience conducting computer and systems analysis to support the management of Drug Safety Systems.
  • 7 years of programming experience employing PL/SQL, C++, MS .Net Framework.
  • 3 years of experience optimizing the use of the Argus Safety software platform.
  • 3 years of experience executing Business Intelligence reporting employing either Cognos, Business Objects, or OBIEE.
Responsibilities
  • Plan, define and execute the high-level computer applications systems analysis necessary to maintain global pharmacovigilance (PV) computer and data systems for the management of the company’s safety data and to ensure the security and integrity of this safety data.
  • Plan and implement optimal systems solutions for the organization's drug safety and PV systems to ensure compliance and data integrity, while also implementing improvements as a result of automating certain IT processes to increase efficiencies and reduce outsourcing costs.
  • Analyze information-technology systems needs and translate these business requirements into detailed technical requirements.
  • Perform system support and configuration planning, and/or application modifications in a compliant manner.
  • Develop, maintain, and oversee full implementation of relevant procedural documents, and templates, including but not limited to SOPs.
  • Provide technical workarounds to the systems engineering and development teams to resolve complex system gaps.
  • Generate and review all data extraction strategies including SAE reconciliation, inspection/audit reports, trending analysis, and other routine business reports.
  • Ensure the compliance of PV computer systems and databases as it relates to regulatory inspections and audits.
  • Ensure relevant data-systems security checks are performed in timely manner for all safety systems.
  • Work with GPS & PV systems vendors to ensure that all safety systems and database are appropriately patched in timely manner.
  • Plan and execute ad hoc database pulls and/or custom report developments to meet business requirements.
  • Will be responsible & accountable for the maintenance of safety applications & tools (data analytics, data entry, medical coding, systems integrity, configuration support, systems compliance, e2b support etc.).
  • Serve as a key contributor for the company’s GPS & PV function ensuring business application systems continuity.
  • Plan and execute integrations, validation, and support User Acceptance Testing(s).
  • Propose improvements/efficiency gains for business processes and support process excellence using a computer information systems perspective.
  • Position to be located in Silver Spring, MD with remote employment within the United States acceptable.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Simplify Jobs

Simplify's Take

What believers are saying

  • Ralinepag Phase 3 triples PAH efficacy, doubles patient base to 30,000 in two years.
  • Tyvaso IPF TETON trials show 100mL lung function gain, NEJM published.
  • $2B share repurchase deploys $1.5B by March 2026 amid $3.8B cash.

What critics are saying

  • Nebulized Tyvaso sales drop 22% YoY as DPI cannibalizes core revenue.
  • Remodulin sales fall 8% YoY from newer PAH competitor pressure.
  • Ralinepag DPI hinges on MannKind; delays collapse PAH expansion.

What makes United Therapeutics Corporation unique

  • United Therapeutics pioneered public benefit corporation structure in 2021 for biotech.
  • Leads xenotransplantation via Revivicor subsidiary engineering donor pigs.
  • Partners with Varda for microgravity drug manufacturing in orbit.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at United Therapeutics Corporation who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Yahoo Finance
Mar 19th, 2026
The Trade Desk and United Therapeutics emerge as mid-cap growth picks while Builders FirstSource stumbles

Here is a summary of the article: Investment analysis platform StockStory has identified two mid-cap stocks worth buying and one to avoid. The Trade Desk, a cloud-based advertising platform, trades at $23.53 per share with a market capitalisation of $11.21 billion. The company posted 22% annual revenue growth over the past two years and boasts a 20.3% operating margin. United Therapeutics, which develops treatments for chronic lung diseases, has a market capitalisation of $23.24 billion. The company achieved 16.9% annual revenue growth over two years whilst demonstrating strong free cash flow generation and improving returns on capital. StockStory advises avoiding Builders FirstSource, a construction materials manufacturer. The company experienced 5.7% annual sales declines over the past two years, with eroding returns on capital and declining earnings per share.

Yahoo Finance
Mar 14th, 2026
United Therapeutics publishes Tyvaso IPF data in NEJM, eyes first inhaled anti-fibrotic approval

United Therapeutics has published full Phase 3 TETON-2 trial data for nebulised Tyvaso in idiopathic pulmonary fibrosis in the New England Journal of Medicine. The study demonstrated preservation of lung function and reduced clinical worsening in IPF patients. If approved by the FDA, Tyvaso would become the first and only inhaled anti-fibrotic treatment for IPF, significantly expanding United Therapeutics' addressable market. The company's shares currently trade at $536.12, with one-year returns of 74.5%. The publication in a top-tier journal represents a significant milestone for the drug developer. Investors are now monitoring potential FDA review milestones and how IPF could influence revenue beyond the current $3.2 billion base, though regulatory or reimbursement challenges remain key risks.

Yahoo Finance
Feb 26th, 2026
United Therapeutics shares drop 7.2% on $790M revenue miss despite earnings beat

United Therapeutics shares fell 7.2% after the biotechnology company reported fourth-quarter revenue of $790.2 million, missing analysts' consensus estimates of over $805 million. Whilst revenue grew 7% year-over-year, Tyvaso sales, though up 12%, also fell short of projections. The company did beat earnings expectations with adjusted earnings of $7.70 per share versus the forecasted $7.10. However, the revenue miss overshadowed the earnings beat, prompting negative market reaction. The stock has shown relatively low volatility over the past year, with only eight moves greater than 5%. United Therapeutics is currently trading at $500.08 per share, near its 52-week high of $535.10. Shares are flat year-to-date.

Yahoo Finance
Feb 26th, 2026
United Therapeutics targets 2026 soft-mist inhaler launch, surpasses $3B in annual revenue

United Therapeutics reported fourth-quarter 2025 results, with full-year revenue surpassing $3 billion for the first time, representing 11% growth. Fourth-quarter revenue reached $790 million, whilst Tyvaso generated $464 million with dry-powder inhaler sales growing 24% year-over-year. The company plans to file its soft-mist treprostinil inhaler, Tresmi, for approval this year, targeting a 2026 commercial launch. Early studies suggest the device could reduce coughing by up to 90% compared to dry-powder alternatives. Near-term catalysts include a once-daily "super prostacyclin" readout next week and TETON-1 IPF trial results next month, with potential launch by June 2027. The company's Zeno xenotransplant programme has transplanted two patients, targeting a commercial product by 2030.

Yahoo Finance
Feb 25th, 2026
United Therapeutics misses Q4 revenue estimates despite 7.4% growth to $790M

United Therapeutics missed Wall Street's revenue expectations in Q4 2025, reporting $790.2 million against estimates of $810.4 million, though sales rose 7.4% year on year. The biotechnology company's GAAP profit of $7.70 per share beat analyst estimates by 14%. The company, which develops treatments for chronic lung diseases and pulmonary hypertension, has demonstrated solid long-term performance with 16.5% annualised revenue growth over five years. However, its operating margin declined to 45.1% from 48.6% in the prior-year quarter. Analysts expect revenue to remain flat over the next 12 months, representing a deceleration from recent growth rates. United Therapeutics has a market capitalisation of $20.38 billion.